loader2
Partner With Us NRI

Ajanta Pharma Ltd share Price

Company details

1,285.20
1,328.00
1,111.60
1,427.50
6M Return 6.49%
1Y Return 14.68%
Mkt Cap.(Cr) 16,472.83
Volume 119,099
Div Yield 0.53%
OI
-
OI Chg %
-
Volume 119,099

Open Free Trading Account Online with ICICIDIRECT

Muted numbers due to transitory issues, branded generics outlook upbeat..

About The Stock

    Ajanta Pharma is a focused player in branded, which constitutes ~72% of overall sales, spread across geographies including India.

    • As of FY22, overall exports: domestic formulations ratio was at 70:30
    • Among exports, Asia accounts for ~35% of export formulations, Africa 34% & US 30%. The company also participates in anti-malarial tenders in Africa (included in Africa)

Q4FY22

    Revenues were above estimates amid strong traction in India and export branded business while margins were sub-par amid 531 bps YoY decline in gross margins to 72.5%.

    • Sales were up 15% YoY to ₹ 870 crore
    • EBITDA was at ₹ 207 crore while margins contracted 1053 bps YoY to 24%
    • Adjusted PAT was at ₹ 151 crore (down 5% YoY)

Click here for full recommendation

Research view on more stocks

Ajanta Pharma Ltd.

Q4FY23 Quarterly & FY23 Annual Result Announced for Ajanta Pharma Ltd.

Ajanta Pharma announced Q4FY23 & FY23 results:

Q4FY23:

  • Revenue from operations at Rs 882 crore against Rs 870 crore; up 1%.
  • EBITDA at Rs 149 crore against Rs 207 crore; EBITDA at 17% of revenue from operations.
  • Profit after tax at Rs 122 crore against Rs 151 crore; PAT at 14% of revenue from operations. 

FY23:

  • Revenue from operations at Rs 3,743 crore against Rs 3,341 crore, up 12%.
  • EBITDA at Rs 783 crore against Rs 929 crore; EBITDA at 21% of revenue from operations.
  • Profit after tax at Rs 588 crore against Rs 713 crore, PAT at 16% of revenue from operations. 

 

Result PDF

View Other Company Results

OUR RESEARCH VIEW

Investment recommendation

Muted numbers due to transitory issues, branded generics outlook upbeat..
Call Date
06 May 2023
Entry Price 1,290.00
Target Price 1,520.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Ajanta Pharma Ltd Stocks COMPARISION

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 3,264.34 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 2,333.12 37,369.27
LAST 3M 16,668.82 53,102.69
LAST 6M 64,410.78 32,565.35
LAST 12M 119,684.93 75,969.00

Ajanta Pharma Ltd Information

Stock PE (TTM)
28.63
Promoter Holding
66.21%
Book Value
264.4538
ROCE
28.91%
ROE
22.77%
Description
  • Ajanta Pharma Limited is in the business of manufacturing and marketing speciality pharmaceutical dosages. The company operates in domestic and various international markets, producing a range of products in therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, paediatric, orthopaedic, respiratory, and cardiology. The company has its headquarters in Mumbai and offices in the USA, Mauritius, and the Philippines. The company was incorporated in 1979, and its market capitalisation, as of 9 October 2022, is Rs 16,148 crore.

    The company is listed on the National Stock Exchange (NSE) under code AJANTPHARM and on the Bombay Stock Exchange (BSE) under code 532331.

    Ajanta Pharma Limited currently sells its products in more than 30 countries across the world and has seven state-of-the-art manufacturing facilities in India. The company’s R&D centre has more than 750 scientists who are developing innovative pharmaceutical products for global markets. Over the years, the company has developed a specialisation in developing generic medicines and process chemistry for domestic as well as international markets.

    In June 2022, the shareholding pattern of Ajanta Pharma Limited revealed a 70.48% stake by promoters, 10.88% stake in mutual funds, 9.30% stake by retail investors, 8.30% stake by Foreign Institutional Investors, and 1.04% stake by other domestic institutions. The management team of the company includes  Mr  Mannalal B Agarwal (Chairman),  Mr  Madhusudan B Agarwal (Vice-Chairman),  Mr  Yogesh Agarwal (Managing Director),  Mr  Chandrakant M Khetan (Independent Director), and  Mr  Gaurang Shah (Company Secretary), among others.

    On 10 October 2022, Ajanta Pharma Limited’s share price closed at Rs 1268.80 at the NSE and Rs 1263.55 at the BSE. The share’s 52-week low and 52-week high prices are Rs 1061.77 and Rs 1577.20, respectively. Ajanta Pharma shares have provided a six-month return of 9.11% and its PE ratio as of 10 October 2022 stood at 22.65, while the PB ratio stood at 0.20. If you want to invest in Ajanta Pharma shares, you can open a demat account with ICICIdirect and place your orders.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose

No Data Found

AGM Date (Month) : Jul
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 532331
NSE Code : AJANTPHARM
Book Closure Date (Month) :
BSE Group : A
ISIN : INE031B01049

FAQ’s on Ajanta Pharma Ltd Shares

You can buy Ajanta Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Ajanta Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 31, 2023 03:56 PM the closing price of Ajanta Pharma Ltd was ₹ 1,308.25.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 31, 2023 03:56 PM, the market cap of Ajanta Pharma Ltd stood at ₹ 16,472.83.

The latest PE ratio of Ajanta Pharma Ltd as of May 31, 2023 03:56 PM is 28.63

The latest PB ratio of Ajanta Pharma Ltd as of May 31, 2023 03:56 PM is 0.20

The 52-week high of Ajanta Pharma Ltd is ₹ 1,427.50 while the 52-week low is ₹ 1,111.60

According to analyst recommendations, Ajanta Pharma Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app